Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,

Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The maker of weight-loss drugs Mounjaro and Zepbound said sales grew slower than expected in the fourth quarter.

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.